Document:

NDC Registration Rights Agreement

  
 Exhibit 10 (iii)

  
 REGISTRATION RIGHTS AGREEMENT 
  
 THIS REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made
and entered into this 31st day of December, 2003, by and between NDCHEALTH CORPORATION, a Delaware corporation (“NDCHealth”), and ARCLIGHT SYSTEMS LLC, a Delaware limited liability company (“Arclight”). 

 
 BACKGROUND: 
  
 A. NDCHealth and Arclight have entered into (i) an Exclusive License Agreement, dated
as of December 31, 2003 (the “License Agreement”), and (ii) a Warrant Agreement, dated as of the date hereof (the “Warrant Agreement”), pursuant to each of which NDCHealth may issue shares of “Common Stock” (as defined
below) to Arclight. 
  
 B. In connection with the transactions contemplated
by the License Agreement, NDCHealth has agreed to grant to Arclight certain registration rights with respect to such shares, all as more particularly described in this Agreement. 
  
 NOW, THEREFORE, FOR AND IN CONSIDERATION of the premises, the mutual promises, covenants and agreements contained
herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
  
 ARTICLE I 
 DEFINITIONS

  
 Capitalized terms used but not defined herein shall have
the respective meanings assigned to such terms in the License Agreement. As used in this Agreement, the following terms shall have the following respective meanings: 
  
 1.1 “Business Day” shall mean any day that is not a Saturday, a Sunday or a day on which banks are required
or permitted to be closed in the State of Georgia. 
  
 1.2
“Common Stock” shall mean the $0.01 par value common stock of NDCHealth. 
  
 1.3 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended. 
  
 1.4 “Holder” shall mean Arclight and any permitted transferee of Arclight. 
  
 1.5 “Person” shall mean any individual, partnership, corporation, trust or other entity. 
  

 1.6 The terms “register,” “registered” and
“registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or order by the SEC of the effectiveness of such registration statement.

  
 1.7 “Registrable Securities” shall mean (i)
the Shares and (ii) any other shares of Common Stock issued by way of (or issuable upon conversion or exercise of any warrant, right or other security which is issued as) a dividend, stock split, combination of shares, recapitalization,
restructuring, merger, consolidation or other distribution with respect to or exchange for or replacement of the Shares; provided, however, that the term “Registrable Securities” shall not include (i) any Shares that have
been registered and sold pursuant to a registration, or (ii) any Shares that have been sold, or could then be sold within any three (3) month period, pursuant to Rule 144 promulgated under the Securities Act. 
  
 1.8 “Securities Act” shall mean the Securities Act of 1933,
as amended. 
  
 1.9 “SEC” shall mean the
Securities and Exchange Commission. 
  
 1.10
“Shares” shall mean (i) the shares of Common Stock issued to Arclight as the “Initial Exclusivity Fee” (as such term is defined in Section 8.1 of the License Agreement), (ii) any shares of Common Stock issued to Arclight
upon Arclight’s exercise of the Warrant Agreement and (iii) any Shares of Common Stock issued to Arclight as the “Additional Contingent Exclusivity Fee” (as such term is defined in Section 8.2 of the License Agreement). 
  
 ARTICLE II 
 DEMAND REGISTRATION 
  
 2.1 Demand Registration. 
  
 (a) From and after the date hereof for a period of 270 days (plus any additional days during which a registration has been postponed pursuant to Section 2.1(f), but in no event beyond one (1) year after the date
hereof), the Holder shall be entitled to have NDCHealth effect one (1) demand registration on Form S-3 (or any applicable substitute, replacement or successor form that may be adopted by the SEC) of the Registrable Securities then owned of record
and beneficially by such Holder; provided, however, (i) that such demand registration shall only be exercisable if Arclight has terminated the License Agreement pursuant to Section 18.2 or Section 18.3 thereof within the nine (9) month
period beginning as of the Closing, and (ii) that NDCHealth shall not be required to effect a demand registration unless the Registrable Securities for which demand is made constitutes all of the Registrable Securities acquired by Arclight as the
Initial Exclusivity Fee. A request for such demand registration (a “Registration Request”) must be made in writing by the Holder. 
  
 (b) NDCHealth shall use its best efforts to cause the Registrable Securities specified in the Registration Request to be registered as
soon as reasonably practicable so as to permit the sale thereof and, in connection therewith, shall, within thirty (30) days after the Holder provides 

  

 2 

 
NDCHealth with such notice, prepare and file a registration statement with the SEC under the Securities Act to effect such registration. 
  
 (c) Such registration statement shall contain such required
information pursuant to the rules and regulations promulgated under the Securities Act and such additional information as deemed necessary by the managing underwriter or, if there is no managing underwriter, as deemed under the Securities Act to be
necessary by NDCHealth. 
  
 (d) In connection
with the preparation of the registration statement, the Holder shall: 
  
 (i) Specify the number of Registrable Securities intended to be offered and sold by the Holder; 
  
 (ii) Express the Holder’s intention to offer or cause the offering of such shares for distribution; 
  
 (iii) Describe the nature or method of the proposed offer
and sale thereof by the Holder; and 
  
 (iv)
Undertake to provide all such information and materials and take all such action as may be required in order to permit NDCHealth to comply with all applicable requirements of the SEC and to obtain any desired acceleration of the effective date of
such registration statement. 
  
 (e)
Notwithstanding the foregoing, if NDCHealth shall furnish to the Holder a certificate signed by a duly authorized officer of NDCHealth stating that in the good faith judgment of the Board of Directors of NDCHealth it would be seriously detrimental
to NDCHealth for such registration statement to be filed on or before the date such filing would be required, then NDCHealth shall be entitled to postpone the filing of the registration statement for up to ninety (90) days; provided, that no period
of postponement shall be counted in tolling the 270-day period referred to in Section 2.1 (except that the one (1) year outside date contained therein shall continue to apply). 
  
 (f) If a registration has become effective but is withdrawn before completion of the offering contemplated
thereby because of adverse business developments at NDCHealth that were not known to the Holder when it requested that NDCHealth initiate such registration proceedings, or which developments came into existence subsequent to such request, such
registration shall not count as the demand registration referred to in the first sentence of this Section 2.1. 
  
 (g) If a registration is filed on behalf of the Holder and such registration is withdrawn at the request of the Holder for any reason
other than adverse business developments at NDCHealth that were not known to the Holder, such registration shall count as the demand registration referred to in the first sentence of this Section 2.1. 
  

 3 

 (h) NDCHealth shall not cause the registration under the Securities Act of any other
shares of Common Stock to become effective (other than the registration of an employee stock plan, or registration in connection with any Rule 145 or similar transaction) during the effectiveness of a registration requested hereunder. 
  
 2.2 Inclusion of Additional Shares. 
  
 (a) NDCHealth may include in a registration pursuant to this
Article II securities for its own account and by other third parties (including officers and employees of NDCHealth or any party to whom similar registration rights have been granted), in amounts as determined by NDCHealth’s Board of Directors.
To the extent NDCHealth includes in such registration statement securities for its own account or held by other parties, NDCHealth shall take all actions it deems reasonably necessary to ensure that security holders of NDCHealth, whether or not
holding contractual registration rights, shall not have the right to exclude from any registration initiated pursuant to this Article II any Registrable Securities of the Holder. 
  
 (b) NDCHealth may enter into an underwriting agreement in customary form with the underwriter or
representative of the underwriters selected for such underwriting. Notwithstanding any other provision of this Section 2.2, if the underwriter or underwriters’ representative advises the Holder in writing that marketing factors require a
limitation on the number of shares to be underwritten, the securities of NDCHealth, the securities held by officers or directors of NDCHealth and the securities held by other third parties shall be excluded from the underwriting by reason of the
underwriter’s marketing limitation to the extent so required by such limitation. No securities excluded from the underwriting by reason of the underwriter’s marketing limitation shall be included in such registration. 
  
 (c) If the Holder disapproves of the terms of the
underwriting, the Holder’s sole remedy shall be to withdraw therefrom by written notice to NDCHealth and the underwriter or the underwriters’ managing representative. The Holder shall be deemed to have withdrawn if the Holder fails to
execute underwriting documents in customary form requested by the underwriter or the underwriters’ managing representative within the time period requested for execution of such documents. 
  
 ARTICLE III 
 PIGGYBACK RIGHTS 
  
 3.1 Notice of Registration. If at any time or from time to time NDCHealth proposes to register (including for this purpose a registration effected by the Company for stockholders of the Company other than the
Holder) under the Securities Act any class of NDCHealth’s equity securities for sale to the public on a registration statement on Form S-1, S-2, S-3 or any applicable substitute, replacement or successor form that may be adopted by the SEC for
the sale of equity securities to the public, then and in each such case NDCHealth, subject to the terms and conditions contained herein, shall: 
  
 (a) Promptly give to the Holder written notice thereof; and 
  

 4 

 (b) Include in such registration (and any related qualification under blue sky laws or
other compliance) and underwriting, the Registrable Securities (subject to cutback as set forth in Section 3.2) specified in a written request or requests made within thirty (30) days after receipt of such written notice from NDCHealth by the Holder
(the “Piggyback Request”). 
  
 3.2 Priority in
Piggyback Registrations. In connection with any offering involving an underwriting of shares of NDCHealth’s equity securities as described in Section 3.1, NDCHealth shall not be required under this Section 3.2 to include any of the
Registrable Securities in such underwriting unless the Holder accepts the terms of the underwriting as agreed upon between NDCHealth and the underwriters selected by it. If the underwriters determine that the amount of Registrable Securities
requested to be included in such registration would jeopardize the success of such offering, then NDCHealth shall be required to include in the offering only that number of Registrable Securities which the underwriters determine in their sole
discretion will not jeopardize the success of the offering. Allocation of securities to be sold in any such offering shall be made first to NDCHealth (unless the offering is pursuant to a contractual demand right, in which case the allocation shall
be made first to the stockholders exercising such demand right) and thereafter, to the extent any other securities are to be included, on a pro-rata basis among the Holder and any other selling stockholders who have contractual rights to include
shares in such offering according to the total number of designated Registrable Securities requested by the Holder and securities requested by such other selling stockholders to be included in such offering and entitled to inclusion therein on the
basis of this Agreement or such other contractual agreement. To facilitate the allocation of shares in accordance with the above provisions, NDCHealth may round the number of Registrable Securities allocated to the Holder or of securities allocated
to each other selling stockholder to the nearest one hundred (100) shares. Notwithstanding anything to the contrary in this Agreement, but subject to the next sentence, the Holder agrees to delay the sale of any Registrable Securities not sold in
such registration for the period requested by the underwriter or managing agent up to ninety (90) days (or such lesser amount of time if permitted by such underwriter or managing agent) following the effective date of the registration statement. The
foregoing restriction shall not apply to the number of Registrable Securities, if any, requested by the Holder to be included in a registration but which are excluded from such registration at the discretion of the underwriters as set forth in this
Section 3.2. 
  
 3.3 Underwriting. The right of the Holder
to registration pursuant to this Article III shall be conditioned upon the Holder’s participation in such underwriting and the inclusion of Registrable Securities in the underwriting to the extent provided herein. If the Holder proposes to
distribute its securities through such underwriting, the Holder shall (together with NDCHealth and any other holders distributing their securities through such underwriting) enter into an underwriting agreement in customary form with the managing
underwriter selected for such underwriting by NDCHealth. 
  
 3.4
Right to Terminate Registration. NDCHealth shall have the right to terminate or withdraw any registration initiated by it under this Article III prior to the effectiveness of such registration, whether or not the Holder has elected to include
securities in such registration. 
  

 5 

 ARTICLE IV 
 OBLIGATIONS OF NDCHEALTH 
  
 4.1 Obligations of NDCHealth. Whenever NDCHealth is required by the provisions of this Agreement to use its best efforts to effect the registration of the Registrable Securities, NDCHealth shall: 
  
 (a) Prepare and file with the SEC a registration statement
with respect to the Registrable Securities, and use its best efforts to cause such registration statement to become effective and to remain effective until the earlier of (i) the sale of the Registrable Securities so registered or (ii) ninety (90)
days subsequent to the effective date of such registration; provided that, not less than three (3) days before filing with the SEC any registration statement or prospectus or not less than one (1) day before filing with the SEC any amendments
or supplements thereto, NDCHealth will furnish to the Holder and its counsel copies of all such documents proposed to be filed, including, without limitation, documents incorporated by reference in the prospectus and, if requested by the Holder, the
exhibits incorporated by reference therein, and the Holder shall have the opportunity to object to any information pertaining solely to the Holder that is contained therein and NDCHealth will make the corrections reasonably requested by the Holder
with respect to such information prior to filing any registration statement or amendment thereto or any prospectus or any supplement thereto. NDCHealth will not include or name the Holder in any registration statement or prospectus without the
consent of the Holder, unless required to do so by the Securities Act and the rules and regulations promulgated thereunder; provided, however, that NDCHealth may withdraw any registration of its securities at any time prior to the
effective date of the registration statement relating thereto; provided, further, that in the event of any such withdrawal such registration shall not count as the demand registration referred to in the first sentence of Section 2.1;

  
 (b) Prepare and, as soon as reasonably
practicable, file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection therewith as may be necessary to make and to keep such registration statement effective and to comply with the
provisions of the Securities Act with respect to the sale or other disposition of all securities proposed to be registered in such registration statement for the applicable period set forth in the foregoing paragraph (a); 
  
 (c) Furnish to the Holder such number of copies of the
registration statement (including any amendment or supplement thereto) and prospectus (including any preliminary prospectus and any amended or supplemented prospectus), in conformity with the requirements of the Securities Act and the rules and
regulations promulgated thereunder, as the Holder may reasonably request in order to effect the offering and sale of the Registrable Securities to be offered and sold, but only while NDCHealth shall be required under the provisions hereof to cause
the registration statement to remain current; 
  
 (d) If necessary, use its best efforts to register or qualify the Registrable Securities covered by such registration statement under the securities or blue sky laws of such states as the Holder shall reasonably request (provided,
however, that NDCHealth shall not be 

  

 6 

 
obligated to qualify as a foreign corporation to do business under the laws of any jurisdiction in which it is not then qualified), maintain any such
registration or qualification current until the earlier of the sale of the Registrable Securities so registered or ninety (90) days subsequent to the effective date of the registration statement, and take any and all other actions either necessary
or advisable to enable the Holder to consummate the public sale or other disposition of the Registrable Securities in jurisdictions where the Holder desires to effect such sales or other disposition; 
  
 (e) NDCHealth shall promptly notify the Holder of any stop
order issued by the SEC and use its best efforts to obtain the withdrawal of any order suspending the effectiveness of the registration statement; 
  
 (f) NDCHealth shall use its best efforts to cause all Registrable Securities covered by each registration statement to be listed subject
to notice of issuance, prior to the date of the first sale of such Registrable Securities pursuant to such registration statement, on each securities exchange on which the Common Stock is then listed and admitted to trading on; 
  
 (g) In the case of an underwritten offering, NDCHealth shall
cause to be delivered to the Holder and the underwriters, if any, copies of opinions of counsel to NDCHealth in customary form, covering such matters as are customarily covered by opinions for an underwritten public offering as the underwriters may
request and addressed to the underwriters; 
  
 (h) NDCHealth shall provide a transfer agent and registrar for all such Registrable Securities not later than the effective date of such registration statement; 
  
 (i) NDCHealth shall cause to be delivered, immediately prior to the effectiveness of the registration
statement (and, in the case of an underwritten offering, at the time of delivery of any Registrable Securities sold pursuant thereto), letters from NDCHealth’s independent certified public accountants addressed to each underwriter, if any,
stating that such accountants are independent public accountants within the meaning of the Securities Act and the applicable published rules and regulations promulgated thereunder, and otherwise in customary form and covering such financial and
accounting matters as are customarily covered by letters of the independent certified public accountants delivered in connection with primary or secondary underwritten public offerings, as the case may be; 
  
 (j) NDCHealth will notify the Holder at any time when a
prospectus relating to a registration statement for any Registrable Securities is required to be delivered under the Securities Act, upon NDCHealth’s discovery that, or upon the happening of any event as a result of which, the prospectus
included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state any material fact required to be stated therein necessary to make the statements therein not misleading in the light of the
circumstances under which they were made, and at the request of the Holder prepare and furnish to the Holder and each underwriter, if any, a reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so
that, as thereafter delivered to the purchasers of such securities, such prospectus shall not include an untrue statement of a material fact or omit to state 

  

 7 

 
a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances under which they
were made; and 
  
 (k) Take all such other
actions either necessary or desirable to permit the Registrable Securities held by the Holder to be registered and disposed of in accordance with the method of disposition described herein. 
  
 4.2 Condition Precedent to NDCHealth’s Obligations. It shall be a
condition precedent to the obligation of NDCHealth to take any action pursuant to this Agreement in respect of the securities which are to be registered at the request of the Holder that the Holder shall furnish to NDCHealth such information
regarding the securities held by the Holder and the intended method of disposition thereof as NDCHealth shall reasonably request and as shall be required in connection with the action taken by NDCHealth. 
  
 ARTICLE V 
 DISCONTINUANCE OF USE OF PROSPECTUS 
  
 The Holder agrees by acquisition of the Shares that, upon receipt of any written notice from NDCHealth of the occurrence of any event of the kind
described in Section 4.1(j), the Holder will forthwith discontinue the Holder’s offer of Shares pursuant to the registration statement relating to such Shares until the Holder’s receipt of the copies of the supplemented or amended
prospectus contemplated by Section 4.1(j) and, if so directed by NDCHealth, will deliver to NDCHealth all copies, other than permanent file copies, then in the Holder’s possession of the prospectus relating to such Shares at the time of receipt
of such notice. In the event that the Holder uses a prospectus in connection with the offering and sale of any of the Shares covered by such prospectus, the Holder will use only the latest version of such prospectus provided by NDCHealth.

  
 ARTICLE VI 
 EXPENSES OF REGISTRATION 
  
 NDCHealth shall pay all of the expenses incurred in connection with any registration statements that are initiated pursuant to this Agreement, including,
without limitation, all SEC and blue sky registration and filing fees, printing expenses, transfer agent and registrar fees, stock exchange qualification fees, the fees and disbursements of NDCHealth’s outside counsel and independent
accountants, including expenses incurred in connection with any special audits incidental to or required by such registration. Any underwriting discounts, fees and disbursements of counsel to the Holder, selling commissions and stock transfer taxes
applicable to the Registrable Securities registered on behalf of the Holder shall be borne by the Holder. 
  
 ARTICLE VII 
 INDEMNIFICATION AND CONTRIBUTION 
  
 7.1 Indemnification by NDCHealth. In the case of each registration
effected by NDCHealth pursuant to this Agreement in which the Holder’s Registrable Securities are 

  

 8 

 
included, NDCHealth agrees to indemnify and hold harmless the Holder and each party, if any, that controls the Holder within the meaning of the Securities
Act and the Holder’s and any such party’s directors and officers against any and all losses, claims, damages or liabilities to which they or any of them may become subject under the Securities Act or any other statute or common law,
including any amount paid in settlement of any litigation, commenced or threatened, if such settlement is effected with the written consent of NDCHealth, and to reimburse them for any reasonable legal or other reasonable expenses incurred by them in
connection with the investigation of any claims and defenses of any actions, insofar as any such losses, claims, damages, liabilities or actions arise out of or are based upon any untrue statement or alleged untrue statement of a material fact
contained in (i) the registration statement, (ii) any preliminary prospectus or final prospectus contained therein, or (iii) any amendment or supplement thereto or any document incorporated by reference therein, or the omission or alleged omission
to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; provided, however, that the indemnification agreement contained in this Section 7.1 shall not (i) apply to such
losses, claims, damages, liabilities or actions of the Holder arising out of, or based upon, any such untrue statement or alleged untrue statement, or any such omission or alleged omission, if such statement or omission was made in reliance upon and
in conformity with information furnished to NDCHealth in writing by the Holder for use in connection with the preparation of the registration statement or any preliminary prospectus or final prospectus contained in the registration statement or any
such amendment thereof or supplement thereto or any document incorporated by reference therein, or (ii) inure to the benefit of any party to the extent such party’s claim for indemnification hereunder arises out of or is based on any violation
by such party of applicable law. 
  
 7.2 Indemnification by the
Holder. In the case of each registration effected by NDCHealth pursuant to this Agreement in which the Holder’s Registrable Securities are included, the Holder shall be obligated, in the same manner and to the same extent as set forth in
Section 7.1, to indemnify and hold harmless NDCHealth and each party, if any, who controls NDCHealth within the meaning of the Securities Act, and NDCHealth’s and any such party’s directors and officers, and the underwriters for such
offering, and each person, if any, who controls any such underwriter within the meaning of the Securities Act, with respect to any untrue statement or alleged untrue statement of a material fact in, or omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading from, such registration statement or any post-effective amendment thereof or any preliminary prospectus or final prospectus (as amended or
supplemented, if amended or supplemented as aforesaid) contained in such registration statement, if such statement or omission was made in reliance upon and in conformity with information furnished in writing to NDCHealth by such indemnifying party
for use in connection with the preparation of such registration statement or any preliminary prospectus or final prospectus contained in such registration statement or any such amendment thereof or supplement thereto; provided,
however, that (x) the indemnification required by this Section 7.2 shall not apply to amounts paid in settlement of any loss, claim, damage, liability or expense if settlement is effected without the consent of the Holder of Registrable
Securities, which consent shall not be unreasonably withheld, and (y) in no event shall the amount of any indemnity under this Section 7.2 exceed the net proceeds from the applicable offering received by the Holder. 
  

 9 

 7.3 Defense of Claims. Each party entitled to indemnification under this Article VII (the
“Indemnified Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and
shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom; provided, that counsel for the Indemnifying Party, who shall conduct the defense of such claim or any litigation
resulting therefrom, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld) and the Indemnified Party may participate in such defense at the Indemnified Party’s expense (unless the Indemnified Party shall
have reasonably concluded that there may be a conflict of interest between the Indemnifying Party and the Indemnified Party in such action, in which case the fees and expenses of counsel shall be at the expense of the Indemnifying Party), and
provided, further, that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Article VII unless, and only to the extent that, the Indemnifying
Party is materially prejudiced thereby. No Indemnifying Party, in the defense of any such claim or litigation shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not
include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. Each Indemnified Party shall furnish such information regarding itself
or the claim in question as an Indemnifying Party may reasonably request in writing and as shall be reasonably required in connection with the defense of such claim and litigation resulting therefrom. 
  
 7.4 Contribution. If the indemnification provided for in this Article
VII is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim, damage or expense referred to herein, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party
hereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the one
hand and of the Indemnified Party on the other hand in connection with the statements or omissions which resulted in such loss, liability, claim, damage or expense, as well as any other relevant equitable considerations. The relative fault of the
Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue (or alleged untrue) statement of a material fact or the omission (or alleged omission) to state a material fact relates to
information supplied by the Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. Notwithstanding anything in this
Section 7.4 to the contrary, in no event shall the Holder’s aggregate liability pursuant to this Agreement exceed the net proceeds from the applicable offering received by the Holder. 
  
 7.5 Limitation. The foregoing indemnity and contribution agreements of
NDCHealth and the Holder are subject to the condition that, insofar as they relate to any loss, claim, liability or damage arising from any misstatement or omission made in a preliminary prospectus, but eliminated or remedied in the amended or
supplemented prospectus on file with the SEC at the time the registration statement in question becomes effective or the amended or supplemented prospectus is filed with the SEC pursuant to SEC Rule 424(b) (the “Final Prospectus”),
such 

  

 10 

 
indemnity or contribution agreement shall not inure to the benefit of any underwriter or the Holder if a copy of the Final Prospectus was furnished to the
underwriter or the Holder and was not furnished to the Person asserting the loss, liability, claim or damage at or prior to the time such action is required by the Securities Act. 
  
 ARTICLE VIII 
 SELECTION OF MANAGING UNDERWRITERS 
  
 Subject to the obligations of NDCHealth under agreements existing on the date hereof, the managing underwriter or underwriters for any offering of Registrable Securities to be registered pursuant to the terms and conditions hereof shall be
selected by NDCHealth. The Holder may not participate in any underwritten offering hereunder unless the Holder: (i) agrees to sell its Registrable Securities on the basis provided in any underwriting arrangements approved by NDCHealth; (ii)
completes and executes powers of attorney, indemnities, underwriting agreements and other documents required under the terms of such underwriting arrangements; (iii) complies with all reasonable requests made by NDCHealth or its counsel with respect
to the registration of the Holder’s Registrable Securities, including, without limitation, providing such information regarding the Holder and the distribution of the Holder’s Registrable Securities. 
  
 ARTICLE IX 
 RULE 144 REPORTING 
  
 With a view to making available the benefits of certain rules and regulations of the SEC which may at any time permit the sale of the Registrable Securities to the public without registration, NDCHealth agrees to use
its best efforts to: 
  
 (a) Make and keep public
information available, as those terms are understood and defined in Rule 144 under the Securities Act; and 
  
 (b) File with the SEC in a timely manner all reports and other documents required of NDCHealth under the Securities Act and the Exchange
Act. 
  
 ARTICLE X 
 TERMINATION 
  
 This Agreement shall terminate (except with respect to Article VII and this Article X, which are intended to survive any termination of this Agreement)
upon the earlier to occur of: (a) the first day after the fifth (5th) anniversary of the Closing on which there are no longer any Registrable Securities; or (b) the seventh (7th) anniversary of the Closing. 
  

 11 

 ARTICLE XI 
 MISCELLANEOUS 
  
 11.1 No Waiver. No failure or delay on the part of any party in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege
preclude other or further exercise thereof or of any other right, power or privilege. 
  
 11.2 Entire Agreement; Amendment. This Agreement constitutes the entire understanding of the parties hereto with respect to the subject matter hereof. This Agreement may be amended only by an agreement in
writing executed by NDCHealth and the Holder. 
  
 11.3
Severability. If any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable, the remaining provisions shall remain in full force and effect. It is declared to be the intention of the parties hereto that
they would have executed the remaining provisions without including any that may be declared unenforceable. 
  
 11.4 Headings; References. Article and Section headings are for convenience only and will not control or affect the meaning or construction of any
provision of this Agreement. Any references to specific Articles or Sections shall be references to Articles or Sections of this Agreement unless expressly stated otherwise. 
  
 11.5 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original,
but all of which together shall constitute the same Agreement, and any signature page of any such counterpart, or any electronic facsimile thereof, may be attached or appended to any other counterpart to complete a fully executed counterpart of this
Agreement, and any telecopy or other facsimile transmission of any signature shall be deemed an original. 
  
 11.6 Notices. All notices and other communications required or permitted hereunder shall be in writing, shall be effective when given, and shall in
any event be deemed to be given upon receipt or, if earlier, (a) five (5) days after deposit with the U.S. Postal Service or other applicable postal service, if delivered by first class mail, postage prepaid, (b) upon delivery, if delivered by hand,
(c) one (1) business day after the business day of deposit with Federal Express or similar overnight courier, freight prepaid or (d) one (1) business day after the business day of facsimile transmission, if delivered by facsimile transmission with
copy by first class mail, postage prepaid, and shall be addressed to the address of such party as set forth beneath such party’s signature hereto, or at such other address as a party may designate by ten days’ advance written notice to the
other parties hereto pursuant to the provisions of this Section 11.6. 
  
 11.7 Successors and Assigns; Assignment. This Agreement shall bind the successors and assigns of the parties hereto, and shall inure to the benefit of any successor or assign of any of the parties hereto. This
Agreement may not be assigned by any party hereto without the prior written consent of the other party or parties; provided, however, that Holder may assign its rights and obligations under this Agreement (other than under Article II) without such
consent to any 

  

 12 

 
transferee of Registrable Securities who is an “Arclight Member” (as such term is defined in the License Agreement), provided such Arclight Member
agrees to be bound by the terms of this Agreement as a “Holder.” 
  
 11.8 Governing Law. The validity and effect of this Agreement and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of Delaware.

  
 IN WITNESS WHEREOF, the undersigned have caused their
respective duly authorized representatives to execute this Agreement as of the day and year first above written. 
  

	“NDCHealth”
	
	NDCHEALTH CORPORATION
		
	By:	 	 
	 	

	 Name:
	 	Randolph L.M. Hutto
	 Title:
	 	Executive Vice President and
Chief Financial Officer
	 Address: 
	 	NDCHealth Corporation
NDCHealth Plaza
Atlanta, Georgia 30329

  

	
	“Arclight”
	
	ARCLIGHT SYSTEMS LLC
		
	By:	 	 
	 	

	 Name:
	 	Mike Buettner
	 Title:
	 	Chief Financial Officer
	 Address: 
	 	 Arclight Systems LLC
c/o Brendan A. Ford

 Executive Vice President - Corporate Department
 Cardinal Health Inc.
7000 Cardinal Place
Dublin, Ohio 43017

  

 13NDC Warrant Agreement

  
 Exhibit 10 (iv)

  
 NEITHER THIS WARRANT NOR THE SECURITIES THAT MAY BE ACQUIRED UPON THE
EXERCISE OF THIS WARRANT: (A) HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY STATE SECURITIES LAWS; AND (B) MAY BE SOLD, PLEDGED, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF IN THE
ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER THE SECURITIES ACT (INCLUDING ANY RULES OR REGULATIONS THEREUNDER) AND ANY APPLICABLE STATE SECURITIES LAWS. 
  
 NDCHEALTH CORPORATION 
  
 WARRANT AGREEMENT 
  
 THIS CERTIFIES that, for value received, ARCLIGHT SYSTEMS LLC, a Delaware limited liability company (the “Holder”), shall be entitled to
acquire from NDCHEALTH CORPORATION, a Delaware corporation (the “Company”), subject to the terms and conditions contained herein, at any time during the period from 9:00 A.M. (Eastern Standard Time) on January 1, 2007, through 5:00
P.M. (Eastern Standard Time) on December 31, 2008 (the “Exercise Period”), 381,098 shares (individually, a “Warrant Share” and collectively, the “Warrant Shares”) of “Common Stock” (as hereinafter defined), at
a purchase price of $26.24 per share (the “Exercise Price”), subject to adjustment from time to time pursuant to the provisions of Section 2. For purposes of this Warrant, the term “Common Stock” shall mean the $0.01 par value
common stock of the Company. 
  
 1. Exercise of Warrants.

  
 1.1 Method of Exercise. The Warrant
evidenced hereby may be exercised by the Holder, in whole or in part, by the delivery at the principal office of the Company (or at such other office or agency of the Company as it may designate by notice in writing to the Holder), during normal
business hours, of this Warrant and the Form of Exercise attached hereto as Schedule A, duly completed and executed by the Holder, and payment (by wire transfer of immediately available United States federal funds or by bank certified,
treasurer’s or cashier’s check payable to the order of the Company) of the aggregate Exercise Price for the Warrant Shares covered by such exercise. 
  

1.2 Cashless Exercise. In lieu of exercising the Warrant evidenced hereby pursuant to Section 1.1 above, the Holder shall have the right
at any time to exercise this Warrant, in whole or in part, by requiring the Company to convert this Warrant (the “Conversion Right”), into Warrant Shares by surrendering this Warrant to the Company accompanied by the Form of Conversion
Notice attached hereto as Schedule B, duly completed and executed by the Holder. Upon exercise of the Conversion Right, the Company shall deliver to the Holder (without payment by the Holder of any cash in respect of the Exercise Price) that
number of Warrant Shares which is equal to the amount obtained by dividing (x) an amount equal to the difference 

 
between (A) the aggregate Market Price for the Warrant Shares as to which the Conversion Right is then being exercised (the “Conversion Shares”),
determined as of the exercise of the Conversion Right, minus (B) the aggregate Exercise Price then applicable to the Conversion Shares (such difference, the “Conversion Amount”), by (y) the Market Price of one share of Common Stock
determined as of the exercise of the Conversion Right. Any references in this Warrant to the “exercise” of this Warrant, and the use of the term “exercise” herein, shall be deemed to include, without limitation, any exercise of
the Conversion Right.  
  
 1.3 Partial
Exercise. In the event this Warrant is not exercised in full, the total number of Warrant Shares shall be reduced by the number of Warrant Shares subject to such partial exercise, and the Company shall promptly issue and deliver to the Holder a
new Warrant of like tenor in the name of the Holder, reflecting such adjusted number of Warrant Shares.  
  
 1.4 Delivery of Certificates. The certificate for the Warrant Shares issued upon exercise of this Warrant by the Holder pursuant to Sections
1.1 or 1.2 shall be delivered to the Holder as soon as practicable after the exercise of this Warrant. The certificate evidencing the Warrant Shares shall bear a restrictive legend substantially in the form set forth below: 
  
 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE: (A) HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY STATE SECURITIES LAWS; AND (B) MAY NOT BE SOLD, PLEDGED, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION OR AN
EXEMPTION THEREFROM UNDER THE SECURITIES ACT (INCLUDING ANY RULES OR REGULATIONS THEREUNDER) AND ANY APPLICABLE STATE SECURITIES LAWS.” 
  
 1.5 No Fractional Shares. In lieu of issuing any fractional shares of Common Stock, the Company shall pay to the Holder cash in an amount
equal to the same fraction of the Market Price of one share of Common Stock determined as of the exercise date of this Warrant. 
  
 2. Adjustments to Exercise Price and Warrant Shares. The Exercise Price and the number of Warrant Shares issuable upon the exercise of the Warrant are
subject to adjustment from time to time upon the occurrence of the events enumerated in this Section 2. 
  
 2.1 Adjustment for Change in Capital Stock. If the Company shall (i) declare a dividend on the Common Stock in shares of its capital stock
(whether shares of Common Stock or of capital stock of any other class), (ii) split or subdivide the outstanding Common Stock, (iii) combine the outstanding Common Stock into a smaller number of shares or (iv) engage in a recapitalization,
reorganization, exchange of shares, spin-off or similar change in capitalization or event, this Warrant shall entitle the Holder to receive the aggregate number and kind of shares which, if this Warrant had been exercised immediately prior to such
time, the Holder would have owned or have become entitled to receive by virtue of such change in capitalization or event at an Exercise Price adjusted for such change in the number of shares purchasable. Such adjustment shall be made successively
whenever any event listed above shall occur and, if a dividend which 

  

 2 

 
is declared is not paid, this Warrant shall again entitle the Holder to receive the number of shares of Common Stock as would have been the case had such
dividend not been declared. Notwithstanding anything to the contrary in this Section 2.1, in no event shall an adjustment to the Exercise Price pursuant to this section result in an aggregate increase in the Exercise Price. This Section 2.1 shall
not apply to any transaction to which Section 2.2 is applicable.  
  
 2.2 Adjustment for Certain Transactions. If the Company consolidates or merges with or into, or sells, transfers or leases all or substantially all of its assets to, any Person, upon consummation of such
transaction this Warrant shall automatically become exercisable in full for the kind and amount of securities, cash or other assets which the Holder of a Warrant would have been entitled to receive in connection with the consolidation, merger, sale,
transfer or lease if the Holder had exercised the Warrant immediately before the effective date of such transaction provided, however, that in the case of a consolidation or merger which would result in the voting securities of the Company
outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving or acquiring entity) at least 50% of the surviving corporation immediately after the closing
thereof, this Warrant shall remain exercisable only during the Exercise Period. Concurrently with the consummation of such transaction, the Person formed by or surviving any such consolidation or merger (if other than the Company), or the Person to
which such sale, transfer or lease shall have been made, shall enter into a supplemental Warrant so providing and further providing for adjustments which shall be as nearly equivalent as may be practical to the adjustments provided for in this
Section 2. The successor Person shall send to the Holder a notice describing the supplemental Warrant. If the issuer of securities deliverable upon exercise of the supplemental Warrant is an Affiliate (as defined in Section 13 hereof) of the formed,
surviving, transferee or lessee Person, that issuer shall join in the supplemental Warrant. Notwithstanding anything to the contrary in this Section 2.2, in no event shall there be an aggregate increase in the Exercise Price. 
  
 2.3 Termination of License Agreement. If the Holder terminates the
License Agreement pursuant to Section 18.2, 18.3 or 18.4 of such agreement, this Warrant shall automatically become exercisable in full. 
  
 2.4 Notices to Holder. 
  
 (a) Upon any adjustment of this Warrant pursuant to this Section 2, the Company shall promptly thereafter (i) cause a certificate to be
executed by the Company setting forth the Exercise Price after such adjustment and setting forth in reasonable detail the method of calculation and the facts upon which such calculations are based and setting forth the number of Warrant Shares
issuable after such adjustment in the Exercise Price, upon exercise of the Warrant in full and payment of the adjusted Exercise Price, and (ii) notify the Holder of such adjustments by sending it a copy of the certificate referenced in the preceding
clause (i). Where appropriate, such notice may be given in advance. 
  

 3 

 (b) The failure to give the notice required by this Section 2.4 or any defect therein
shall not affect the legality or validity of the transaction to which it relates. 
  
 3. Payment of Taxes. The Company shall pay all documentary stamp taxes, if any, attributable to the initial issuance of Warrant Shares upon exercise of the Warrant. The Company shall not, however, be required to pay any tax or
taxes which may be payable in respect of any transfer involved in the issuance and delivery of this Warrant, or any supplemental or replacement Warrant, or any certificate for Warrant Shares or other securities, and the Company shall not be required
to issue or deliver any such supplemental or replacement Warrants or certificates unless and until the Person(s) requesting the issuance thereof shall have paid to the Company the amount of such tax or shall have established to the satisfaction of
the Company that such tax has been paid. 
  
 4. Certain
Covenants. 
  
 4.1 The Company shall at all times reserve
and keep available, free from preemptive rights, out of the aggregate of its authorized but unissued Common Stock or its authorized and issued Common Stock held in its treasury, for the purpose of enabling it to satisfy any obligation to issue
Warrant Shares upon exercise of this Warrant, the maximum number of Warrant Shares which may then be deliverable upon the exercise in full of this Warrant. 
  
 4.2 The Company shall (i) use its best efforts to comply with the current public information requirements of Rule 144 (“Rule 144”) under the
Securities Act and (ii) at all times Rule 144 is available for use by Holder, furnish the Holder upon request with all information within the possession of the Company, required for the preparation and filing of Form 144. As soon as reasonably
practicable after January 1, 2007, or at such time as the Warrant Shares otherwise become exercisable pursuant to the terms hereof, NDCHealth shall, to the extent required by the rules of the NYSE, file with the NYSE a listing application or other
notice as may be required with respect to the Warrant Shares and use its commercially reasonable efforts to obtain approval for the listing of such shares.  
  
 5. Representations and Warranties. 
  
 5.1 The Company hereby represents and warrants to the Holder as follows: 
  
 (a) This Warrant has been duly authorized by all necessary corporate action on the part of the Company and
has been duly executed by a duly authorized officer of the Company and constitutes a valid and binding obligation of the Company. 
  
 (b) Neither the execution and delivery of this Warrant, nor the consummation of the transactions contemplated hereby, will violate or
result in any violation of or be in conflict with or constitute a default under any term of the charter or bylaws of the Company or of any agreement, instrument, judgment, decree, order, statute, rule or governmental regulation applicable to the
Company. 
  

 4 

 (c) All Warrant Shares which may be issued upon the exercise of this Warrant, when issued
in accordance with the terms hereof, shall be duly authorized, validly issued, fully paid and nonassessable. 
  
 5.2 The Holder hereby represents and warrants to the Company (which shall be affirmed by the Holder on the date of the exercise of this Warrant) that (a)
this Warrant and the Warrant Shares issuable upon exercise of this Warrant (collectively, the “NDCHealth Securities”) are being acquired for the Holder’s own account, for investment purposes only, and not with a view to any
distribution or resale thereof; and (b) the Holder is a sophisticated investor with knowledge and experience in financial matters, is capable of evaluating the merits and risks of an investment in the NDCHealth Securities, has the capacity to
protect its own interests in connection with the transactions contemplated by this Agreement, is able to bear the economic risk of its investment in the NDCHealth Securities, is presently able to afford the complete loss of such investment, and is
an “accredited investor” (as defined in Rule 501 of Regulation D promulgated under the Securities Act). 
  
 6. Holder; No Rights as Shareholder. The Holder shall be deemed the owner of this Warrant for all purposes. The Holder shall not be entitled by
virtue of ownership of this Warrant to any rights whatsoever as a shareholder of the Company with respect to the Common Stock issuable upon exercise of this Warrant, either at law or in equity, including, without limitation, the right to vote and to
receive dividends and other distributions. 
  
 7. Restrictions on
Transfer. 
  
 7.1 The Holder may not Transfer this Warrant
to any Person other than an Affiliate without the express prior written consent of the Company, and any Transfer in violation of this Section 7 shall be void and of no force or effect. In the event that the Company consents to any Transfer requested
by the Holder to any Person (a “Proposed Transferee”), such Transfer shall be conditioned upon the receipt of an opinion of counsel reasonably satisfactory to the Company that such Transfer to a Proposed Transferee would not result in a
violation of the provisions of the Securities Act and applicable state securities laws. 
  
 7.2 Each Holder of this Warrant and any Warrant Shares issued upon exercise of this Warrant, by taking or holding the same, consents to and agrees to be bound by the provisions of this Section 7. 
  
 8. Lost Warrant. Upon receipt by the Company at its principal office of
evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant, and in the case of any such loss, theft, or destruction, upon delivery of indemnity reasonably satisfactory to the Company or, in case of
any such mutilation, upon surrender and cancellation of this Warrant, the Company will issue a new Warrant of like tenor in lieu of this Warrant. 
  
 9. Expiration. This Warrant, in all events, shall be wholly void and have no effect after 5:00 P.M. (Eastern Standard Time) on December 31, 2008.

  

 5 

 10. Notices. All notices, consents or other communications required or permitted to be given under this
Agreement shall be in writing and shall be deemed to have been duly given (a) when delivered personally, or (b) one business day after being sent by a reputable overnight delivery service, postage or delivery charges prepaid (provided that
confirmation of delivery is obtained from such service), to the parties at their respective addresses set forth below: 
  
 If to the Company: 
  
 NDCHealth Corporation 
 NDC Plaza

 Atlanta, Georgia 30329-2010 
 Attention: Chief Executive Officer 
  
 with a copy to:

  
 Stephen E. Lewis 
 Troutman Sanders LLP 
 600 Peachtree Street,
NE, Suite 5200 
 Atlanta, Georgia 30308-2216 
  
 If to the Holder: 
  
 Arclight Systems LLC 
 c/o Brendan A. Ford

 Executive Vice President-Corporate Development 
 Cardinal Health Inc. 
 7000 Cardinal Place 
 Dublin, Ohio 43017 
  
 with a copy to: 
  
 Gary D. Gerstman 
 Sidley Austin Brown &
Wood LLP 
 Bank One Plaza 
 10
S. Dearborn Street 
 Chicago, Illinois 60603 
  
 Notices may also be given by prepaid telegram or facsimile and shall be effective on the date transmitted if confirmed within 24 hours thereafter by a
signed original sent in the manner provided above. Any party may change its address for notice and the address to which copies must be sent by giving notice of the new addresses to the other parties in accordance with this Section 10, except that
any such change of address notice shall not be effective unless and until received. 
  

 6 

 11. Severability. In the event that one or more of the provisions of this Warrant shall for any reason be
held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision of this Warrant, but this Warrant shall be construed as if such invalid, illegal or unenforceable
provision had never been contained herein. 
  
 12. Governing Law.
This Warrant shall be governed by and construed in accordance with the laws of the State of Delaware applicable to agreements made and to be entirely performed within such State without giving effect to principles of conflicts of laws. 

 
 13. Definitions. As used in this Agreement: 
  
 (a) “Affiliate” means any Person that directly or
indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, the Person specified. The terms “control,” “controlled by” and “under common control with” means the
possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, as general partner, as a limited partner with a right to receive fifty
percent (50%) or more of the income or assets of a limited partnership, by contract or otherwise. 
  
 (b) “Market Price” means as of the date of determination, the last sale price for the Common Stock on the principal securities
market or exchange on which the Common Stock is listed or admitted to trading averaged over a period of ten (10) consecutive trading days ending on the last trading day prior to the date of the exercise of this Warrant. If at any time the Common
Stock is not listed on any market or exchange, the Market Price of the Common Stock shall be deemed to be the higher of (i) the book value thereof, as determined in accordance with generally accepted accounting principles consistent with those then
being applied by the Company by any firm of independent certified public accountants (which may be the regular auditors of the Company) of recognized national standing selected by the Board of Directors of the Company, as of the last day of the
month ending within thirty-one (31) days preceding the date of the exercise of this Warrant, and (ii) the fair market value thereof as of a date which is within fifteen (15) days preceding the date of the exercise of this Warrant, as determined by
an independent material brokerage firm selected by the Company and reasonably acceptable to the Holder. 
  
 (c) “NYSE” means the New York Stock Exchange, Inc. 
  
 (d) “Person” means any individual, sole proprietorship, joint venture, partnership, corporation,
association, cooperative, trust, estate, governmental body, administrative agency, regulatory authority or other entity of any nature. 
  
 (e) “Transfer” means to dispose of or part with all or any portion of an interest (legal or equitable) by any means, direct or
indirect, absolute or conditional, voluntary or involuntary, including, but not limited to, by sale, assignment, disposition, court order, operation of law, dissolution, merger, consolidation, division, spin-off, dividend, distribution, equitable or
other distribution after divorce or separation, settlement, exchange, waiver, abandonment, gift, alienation, bequest, pledge, hypothecation, encumbrance or disposal. 
  

 7 

 14. Neutral Construction. The parties have negotiated this Warrant and all of the terms and conditions
contained in this Warrant in good faith and at arms’ length, and each party has been represented by counsel during such negotiations. No term, condition, or provision contained in this Agreement shall be construed against any party or in favor
of any party because such party or such party’s counsel drafted such term, condition, or provision. Furthermore, all terms, conditions, and provisions contained in this Warrant shall be construed and interpreted in a manner which is consistent
with all other terms, conditions, and provisions contained in this Warrant. 
  
 15. Counterparts. This Warrant may be executed in one or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument. 
  
 IN WITNESS WHEREOF, NDCHealth Corporation and the Holder have caused
this Warrant to be signed by a duly authorized officer and dated as of December 31, 2003. 
  

	 NDCHEALTH CORPORATION

		
	 By:
	 	 
	 	

	 	 	 Randolph L.M. Hutto, Executive Vice
 President and Chief Financial Officer

  

	 ARCLIGHT SYSTEMS LLC

		
	 By:
	 	 
	 	

	 	 	Mike Buettner, Chief Financial Officer

  

 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}]]